ADPT - Adaptive Biotechnologies Corporation
NEXT EARNINGS:
May 7, 2026
EPS Est: $-0.16
|
Rev Est: $60.7M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$21.25
DETAILS
HIGH:
$22.00
LOW:
$21.00
MEDIAN:
$21.00
CONSENSUS:
$21.25
UPSIDE:
32.40%
Market Cap:
2.45B
Volume:
1,542,811
Avg Volume:
2,259,188
52 Week Range:
6.255-20.76
Sector:
Healthcare
Industry:
Biotechnology
Beta:
2.18
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
619
IPO Date:
2019-06-27
EPS (TTM):
-0.39
P/E Ratio:
-41.41
Revenue (TTM):
276.98M
Total Assets:
512.74M
Total Debt:
280.58M
Cash & Equiv:
70.50M
Rev Growth (5Y):
23.0%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-11.3%
Debt/Equity:
1.28
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-05 | $-0.09 | $-0.19 | +52.6% | $71.7M | $58.5M | +22.6% |
| 2025-11-05 | $-0.15 | $-0.16 | +6.3% | $94.0M | $59.4M | +58.2% |
| 2025-08-05 | $-0.17 | $-0.24 | +29.2% | $58.9M | $55.4M | +6.3% |
| 2025-05-01 | $-0.20 | $-0.28 | +28.6% | $52.4M | $42.1M | +24.5% |
| 2025-02-11 | $-0.23 | $-0.27 | +14.8% | $47.5M | $46.0M | +3.1% |
| 2024-11-07 | $-0.22 | $-0.30 | +26.7% | $46.4M | $40.2M | +15.5% |
| 2024-08-01 | $-0.26 | $-0.32 | +18.8% | $43.2M | $40.6M | +6.5% |
| 2024-05-07 | $-0.33 | $-0.35 | +5.7% | $41.9M | $38.8M | +8.0% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 276.98M | 178.96M | 170.28M | 185.31M | 154.34M | 98.38M | 85.07M | 55.66M | 38.45M |
| Net Income | (59.50M) | (159.49M) | (225.25M) | (200.19M) | (207.28M) | (146.23M) | (68.61M) | (46.45M) | (42.83M) |
| EPS | -0.39 | -1.08 | -1.56 | -1.00 | -1.46 | -1.06 | -0.47 | -0.44 | -0.41 |
| Total Assets | 512.74M | 539.38M | 661.13M | 856.62M | 923.34M | 1.12B | 912.30M | 332.69M | 362.49M |
| Total Debt | 280.58M | 89.39M | 98.77M | 108.00M | 111.74M | 107.86M | 36.61M | 561.19M | 561.67M |
| Cash & Equivalents | 70.50M | 47.92M | 65.06M | 90.03M | 139.06M | 123.44M | 96.58M | 55.03M | 85.31M |
| Operating Cash Flow | 0 | (95.21M) | (156.32M) | (183.94M) | (192.73M) | (149.68M) | 205.40M | (32.26M) | (34.86M) |
| Free Cash Flow | 0 | (98.88M) | (167.02M) | (200.29M) | (254.47M) | (168.49M) | 194.20M | (38.58M) | (37.36M) |
| FCF per Share | N/A | -0.67 | -1.16 | -1.41 | -1.81 | -1.28 | 1.56 | -0.37 | -0.35 |
| Book Value | 218.79M | 202.71M | 308.40M | 464.17M | 603.99M | 743.27M | 571.04M | (258.11M) | (224.62M) |
| Cash & ST Investments | 226.98M | 222.29M | 346.40M | 498.20M | 353.06M | 688.27M | 576.87M | 165.02M | 192.15M |
| ROC Equity | -0.27 | -0.79 | -0.73 | -0.43 | -0.34 | -0.20 | -0.12 | N/A | N/A |